More Realistic Forecasting of Future Life Events After Psilocybin for Treatment-Resistant Depression

被引:37
作者
Lyons, Taylor [1 ]
Carhart-Harris, Robin Lester [1 ]
机构
[1] Imperial Coll London, Dept Med, Psychedel Res Grp, London, England
来源
FRONTIERS IN PSYCHOLOGY | 2018年 / 9卷
关键词
treatment-resistant depression; psilocybin; cognitive bias; pessimism; forecasting; LYSERGIC-ACID DIETHYLAMIDE; DEFAULT-MODE NETWORK; MYSTICAL-TYPE EXPERIENCES; 5-HT2A RECEPTOR-BINDING; DYSFUNCTIONAL ATTITUDES; SPIRITUAL SIGNIFICANCE; UNREALISTIC OPTIMISM; POSITIVE ILLUSIONS; THREATENING CANCER; HEALTHY-SUBJECTS;
D O I
10.3389/fpsyg.2018.01721
中图分类号
B84 [心理学];
学科分类号
04 ; 0402 ;
摘要
Background: Evidence suggests that classical psychedelics can promote enduring changes in personality, attitudes and optimism, as well as improvements in mental health outcomes. Aim: To investigate the effects of a composite intervention, involving psilocybin, on pessimism biases in patients with treatment-resistant depression (TRD). Methods: Patients with TRD (n = 15) and matched, untreated non-depressed controls (n = 15) performed the Prediction Of Future Life Events (POFLE) task. The POFLE task requires participants to predict the likelihood of certain life events occurring within a 30day period, after which the actual rate of event occurrence is reported; this gives an index of potential pessimism versus optimism bias. Psilocybin was administered in two oral dosing sessions (10 and 25 mg) one week apart. Main outcome measures were collected at baseline and one week after the second dosing session. Results: Patients showed a significant pessimism bias at baseline [t(14) = 3.260, p = 0.006; 95% CI (-0.16, -0.03), g = 1.1] which was related to the severity of their depressive symptoms (r(s) = 0.55, p = 0.017). One week after psilocybin treatment, this bias was significantly decreased [t(14) = 2.714, p = 0.017; 95% CI (-0.21, -0.02), g = 0.7] and depressive symptoms were greatly improved [t(14) = 7.900, p < 0.001; 95% CI (16.17, 28.23), g = 1.9]; moreover, the magnitude of change in both variables was significantly correlated (r = -0.57, p = 0.014). Importantly, post treatment, patients became significantly more accurate at predicting the occurrence of future life events [t(14) = 1.857, p = 0.042; 95% CI (-0.01, 0.12), g = 0.6] whereas no such change was observed in the control subjects. Conclusion: These findings suggest that psilocybin with psychological support might correct pessimism biases in TRD, enabling a more positive and accurate outlook.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
    Carhart-Harris, Robin L.
    Bolstridge, Mark
    Rucker, James
    Day, Camilla M. J.
    Erritzoe, David
    Kaelen, Mendel
    Bloomfield, Michael
    Rickard, James A.
    Forbes, Ben
    Feilding, Amanda
    Taylor, David
    Pilling, Steve
    Curran, Valerie H.
    Nutt, David J.
    LANCET PSYCHIATRY, 2016, 3 (07): : 619 - 627
  • [22] A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review
    Wong, Sabrina
    Kwan, Angela T. H.
    Teopiz, Kayla M.
    Le, Gia Han
    Meshkat, Shakila
    Ho, Roger
    d'Andrea, Giacomo
    Cao, Bing
    Di Vincenzo, Joshua D.
    Rosenblat, Joshua D.
    McIntyre, Roger S.
    JOURNAL OF AFFECTIVE DISORDERS, 2024, 350 : 698 - 705
  • [23] An Open Label Pilot of The Safety and Efficacy of Comp360 Psilocybin in Patients With Severe Treatment-Resistant Depression
    Aaronson, Scott
    Miller, Tammy
    Rudow, Samuel
    Forbes, MacKenzie
    Shoultz, Audrey
    Suppes, Trisha
    NEUROPSYCHOPHARMACOLOGY, 2022, 47 (SUPPL 1) : 196 - 197
  • [24] Role of Psychedelics in Treatment-Resistant Depression
    Kamal, Shubham
    Jha, Manish Kumar
    Radhakrishnan, Rajiv
    PSYCHIATRIC CLINICS OF NORTH AMERICA, 2023, 46 (02) : 291 - 305
  • [25] The Genetics of Treatment-Resistant Depression: A Critical Review and Future Perspectives
    Fabbri, Chiara
    Corponi, Filippo
    Souery, Daniel
    Kasper, Siegfried
    Montgomery, Stuart
    Zohar, Joseph
    Rujescu, Dan
    Mendlewicz, Julien
    Serretti, Alessandro
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2019, 22 (02) : 93 - 104
  • [26] Treatment-resistant depression: therapeutic trends, challenges, and future directions
    Al-Harbi, Khalid Saad
    PATIENT PREFERENCE AND ADHERENCE, 2012, 6 : 369 - 388
  • [27] Long-term quality of life in treatment-resistant depression after electroconvulsive therapy
    Lex, Heidemarie
    Nevers, Steven W.
    Jensen, Erica L.
    Ginsburg, Yarden
    Maixner, Daniel F.
    Mickey, Brian J.
    JOURNAL OF AFFECTIVE DISORDERS, 2021, 291 : 135 - 139
  • [28] Open Label Psilocybin Administration in Severely Treatment Resistant Depression
    Aaronson, Scott
    Miller, Tammy
    Rudow, Samuel
    Forbes, MacKenzie
    Suppes, Trisha
    BIOLOGICAL PSYCHIATRY, 2022, 91 (09) : S244 - S244
  • [29] Failure of hippocampal deactivation during loss events in treatment-resistant depression
    Johnston, Blair A.
    Tolomeo, Serenella
    Gradin, Victoria
    Christmas, David
    Matthews, Keith
    Steele, J. Douglas
    BRAIN, 2015, 138 : 2766 - 2776
  • [30] Return of the psychedelics: Psilocybin for treatment resistant depression
    Patra, Suravi
    ASIAN JOURNAL OF PSYCHIATRY, 2016, 24 : 51 - 52